![Monovalent antibody design and mechanism of action of onartuzumab, a MET antagonist with anti-tumor activity as a therapeutic agent]()
Monovalent antibody design and mechanism of action of onartuzumab, a MET antagonist with anti-tumor activity as a therapeutic agentMerchant, M.; Ma, X.; Maun, H. R.; Zheng, Z.; Peng, J.; Romero, M.; Huang, A.; Yang, N.-y.; Nishimura, M.; Greve, J.; Santell, L.; Zhang, Y.-W.; Su, Y.; Kaufman, D. W.; Billeci, K. L.; Mai, E.; Moffat, B.; Lim, A.; Duenas, E. T.; Phillips, H. S.; Xiang, H.; Young, J. C.; Vande Woude, G. F.; Dennis, M. S.; Reilly, D. E.; Schwall, R. H.; Starovasnik, M. A.; Lazarus, R. A.; Yansura, D. G. · Proceedings of the National Academy of Sciences · 2013